T. Rowe Price Investment Management Reduces $216M in Ionis Pharmaceuticals, Inc. ($IONS)
Key Points
- T. Rowe Price Investment Management changed its Ionis Pharmaceuticals, Inc. ($IONS) stake by 32.4% last quarter, cutting to 6,159,027 shares worth $451.33 million.
- Wall Street's consensus rating on $IONS is Buy and an average price target of $102.17.
- $IONS last traded around $73.28.
T. Rowe Price Investment Management reduced its position in Ionis Pharmaceuticals, Inc. ($IONS) by 32.4% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,159,027 shares of Ionis Pharmaceuticals, Inc. after selling 2,948,992 shares during the quarter. T. Rowe Price Investment Management's holdings in Ionis Pharmaceuticals, Inc. were worth $451.33 million as of its most recent filing.
Ionis Pharmaceuticals, Inc. ($IONS) Stock
Ionis Pharmaceuticals, Inc. Earnings
Analysts Set New Price Targets
About Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.